600488 津药药业
2024/06 - 中期
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入1,800,984-10.99%3,782,8273,688,9303,748,6653,116,848
减:营业总成本1,568,445-13.87%3,590,1763,485,9793,566,7212,951,809
    其中:营业成本968,875-2.68%2,026,6431,878,6681,963,0271,682,910
               财务费用3,203-52.02%17,21129,24845,23544,358
               资产减值损失(53,748)33.51%(57,226)(123,935)(53,351)(45,103)
公允价值变动收益0-100.00%--------
投资收益1,041-277.21%(1,126)(22,437)4,985(1,221)
    其中:对联营企业和合营企业的投资收益1,037-458.78%(266)(1,952)1,615(1,221)
营业利润192,67113.74%169,40770,208145,834132,421
利润总额194,33115.25%168,24012,517149,067112,380
减:所得税费用16,92827.27%5,567(5,920)40,40031,805
净利润177,40314.22%162,67318,437108,66880,575
减:非控股权益35,38310.86%45,621(16,969)60,00046,596
股东净利润142,02015.08%117,05335,40648,66833,979

市场价值指针
每股收益 (元) *0.13015.04%0.1070.0320.0450.031
每股派息 (元) *----0.0870.0100.0140.010
每股净资产 (元) *2.746-2.66%2.7002.7112.7212.718
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容